Orchestra BioMed Holdings, Inc. (OBIO)
- Previous Close
7.99 - Open
7.90 - Bid 7.84 x 100
- Ask 8.11 x 100
- Day's Range
7.82 - 8.09 - 52 Week Range
4.22 - 14.87 - Volume
53,478 - Avg. Volume
57,195 - Market Cap (intraday)
285.592M - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-1.46 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.33
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
orchestrabiomed.comRecent News: OBIO
Performance Overview: OBIO
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OBIO
Valuation Measures
Market Cap
285.59M
Enterprise Value
212.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
126.97
Price/Book (mrq)
4.99
Enterprise Value/Revenue
95.75
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.05%
Return on Equity (ttm)
-65.81%
Revenue (ttm)
2.22M
Net Income Avi to Common (ttm)
-51.64M
Diluted EPS (ttm)
-1.46
Balance Sheet and Cash Flow
Total Cash (mrq)
75.04M
Total Debt/Equity (mrq)
2.84%
Levered Free Cash Flow (ttm)
-25.09M